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https://doi.org/10.1016/j.celrep.2021.109649SUMMARYCAG repeat expansion in the HTT gene drives Huntington’s disease (HD) pathogenesis and is modulated by
DNA damage repair pathways. In this context, the interaction between FAN1, a DNA-structure-specific
nuclease, and MLH1, member of the DNA mismatch repair pathway (MMR), is not defined. Here, we identify
a highly conserved SPYFmotif at the N terminus of FAN1 that binds toMLH1. Our data support amodel where
FAN1 has two distinct functions to stabilize CAG repeats. On one hand, it binds MLH1 to restrict its recruit-
ment byMSH3, thus inhibiting the assembly of a functionalMMRcomplex that would otherwise promoteCAG
repeat expansion. On the other hand, it promotes accurate repair via its nuclease activity. These data high-
light a potential avenue for HD therapeutics in attenuating somatic expansion.INTRODUCTION
Huntington’s disease (HD) is a monogenic neurodegenerative
condition arising due to inheritance of R36 CAG repeats in
exon 1 of the huntingtin (HTT) gene. Expansion of CAG repeats
occurs in selected somatic and selected meiotic tissues, but
the neurodegeneration is primarily due to loss of neurons in the
striatum and cortex (MacDonald et al., 1993; Pinto et al., 2013;
Rikitake et al., 2020; Tomé et al., 2013). Faster somatic expan-
sion rates correlate with earlier age at onset and faster disease
progression (Bates et al., 2015; Rawlins et al., 2016; Flower
et al., 2019; Swami et al., 2009; Wright et al., 2019). The
expanded CAG repeat may be pathogenic through several
mechanisms, including at the protein level through translation
into a longer, more toxic polyglutamine tract; at the RNA level
through the incomplete splicing ofHTT (Neueder et al., 2017; Sa-
thasivam et al., 2013), RAN translation, or RNA secondary struc-
ture (Bañez-Coronel et al., 2015; Schilling et al., 2016) ; and at the
DNA level through an effect on transcription and DNA repair ac-
tivity (Wright et al., 2020). Targeting repeat expansion, the mostThis is an open access article undproximal pathogenic event, represents a prime therapeutic op-
portunity in HD and potentially other trinucleotide disorders (Tab-
rizi et al., 2020). In recent years, several genome-wide associa-
tion studies (GWASs) have identified DNA repair genes as main
modifiers of HD onset and progression (GeM-HD Consortium,
2019). The strongest signal comes from genetic variation in the
DNA repair gene FAN1, a nuclease of the Fanconi anemia (FA)
pathway (MacKay et al., 2010; Smogorzewska et al., 2010),
while other prominent modifications are in MSH3, MLH1,
andPMS2, members of themismatch repair (MMR) pathway (Jir-
icny, 2006). Similarly, transcriptome-wide association studies
(TWASs) show a signature in which reducedMSH3 but increased
FAN1 expression are associated with later onset, slower pro-
gression, and CAG repeat stability (Flower et al., 2019; Goold
et al., 2019).We and others have demonstrated in cell and animal
models that deficiency of MSH3, MSH2, MLH3, PMS2, and
MLH1 or increased expression of FAN1 (Tomé et al., 2013; Pinto
et al., 2013; Miller et al., 2020) prevents somatic expansion. This
is consistent with analyses linking FAN1 loss-of-function vari-
ants, such as p.R507H (GeM-HD Consortium, 2019), with earlierCell Reports 36, 109649, August 31, 2021 ª 2021 The Author(s). 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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OPEN ACCESSonset. Therefore, in the context of HD, FAN1 expression has a
dose-dependent protective effect on CAG repeat expansion,
providing a credible mechanism for its defensive influence
in vivo.
Despite this, the molecular relationship between MMR and
FAN1 is not well understood. MMR relies on the MutSb hetero-
dimer (MSH3-MSH2) to recognize large loops in slipped DNA
and to recruit MutLa (MLH1-PMS2) to incise DNA through its
endonuclease activity. Thereafter, repair is conducted by a
DNA polymerase and ligase 1 (LIG1), incorporating additional
CAG repeat units. On the other hand, FAN1 is an endonuclease
and 50–30 exonuclease that excises aberrant interstrand cross-
links (ICLs) that impair transcription and ensures the recovery
of stalled replication forks (Huang and D’Andrea, 2010; Lachaud
et al., 2016; Chaudhury et al., 2014). How FAN1 protects against
CAG repeat instability remains unclear, with some data suggest-
ing FAN1’s DNA-binding capacity may be important (Kim et al.,
2020). Interestingly, FAN1 interacts directly with MLH1 (Pinto
et al., 2013; Rikitake et al., 2020; Tomé et al., 2013) but, to our
knowledge, the nature and purpose of this interaction has not
been explored in a HD context. Recent evidence in a HD mouse
model supports the protective effect of FAN1 at CAG repeats
and shows that it acts through MLH1 (Loupe et al., 2020). These
physical and genetic links prompted us to further investigate the
mechanistic significance of the FAN1-MLH1 relationship.
Using the U2OS cell line, well established in the FAN1 field
(MacKay et al., 2010; Munoz et al., 2014), we show that an evolu-
tionary conserved functional domain of FAN1 (126SPYF129) is
responsible for binding MLH1 and is important for CAG repeat
stability. Additionally, we highlight the in vivo relevance of this
interaction by demonstrating that FAN1 binds MLH1 in multiple
human and mouse HD models. The FAN1-MutL interaction pre-
vents the recruitment of MLH1 to the MutSb complex, therebyFigure 1. The FAN1 N-terminal region (p.73-349) mediates its interacti
(A) CoIP extracts from human HD iPSCs showing FAN1 interacts with MutLa co
fraction (n = 3 biological replicates).
(B) CoIP extracts from human HD lymphoblasts confirming FAN1 interacts with M
(C) Pull-down assays using GFP-Trap beads in U2OS cells showing FAN1 interact
nuclear antigen). FAN1/ cells act as a negative control, demonstrating specific
(D) CoIP of cortical extracts from mouse zQ175 at 6 months of age confirming FA
12 weeks of age (zQ175, n = 3 biological replicates; R6/2, n = 2 biological replic
(E) Crosslinks identified between FAN1, MLH1, and PMS2 in unstimulated HEK
unsolved (no PDB structure available). Turquoise line, interprotein; purple line, intra
Table S1.
(F) Schematic illustrating FAN1 constructs cloned into U2OS system. Locations o
UBZ, ubiquitin-binding zinc-finger domain; SAP, SAF-A/B, Acinus and PIAS dom
repair nuclease domain.
(G) Pull-down using GFP-Trap beads in U2OS cells expressing GFP-FAN1 deletio
that inactivation of UBZ or VRR_NUCdomains (C44A/C47A andD960Amutants, r
(H) CoIP extracts using aMLH1 antibody in U2OS cells showing N-terminal FAN1
(I) MMC viability curves in U2OS cells expressing FAN1 variants (mean ± SD) s
biological replicates; n = 3 technical replicates). See also Figure S1E.
(J) CAG expansion rates in U2OS cells expressing truncated FAN1 constructs, inc
D960A). Note that only FAN1D73–349 shows a higher expansion rate than cells expr
replicates, n = 3–6 technical replicates, F(5,97) = 40.8, p < 0.001 by one-way AN
significant.
(K–M) Fragment analysis traces illustrating expansion of the exogenous HTT 118
(K) with time courses plotted (L and M). Note that cells expressing FAN1D73–34
FAN11–349 (individual data points shown) and FAN1/ cells (mean ± SD, 95% c
technical replicates).reducing somatic expansion. We further show that FAN1’s
nuclease activity plays an active role in suppressing expansion.
Therefore, promoting the FAN1-MutL complex interaction repre-
sents an unexplored therapeutic strategy in HD and potentially
other trinucleotide disorders.
RESULTS
FAN1-MLH1 binding demonstrated in vitro and in vivo in
multiple HD models
Because of the strong genetic evidence linking FAN1 and MMR
proteins in the pathogenesis of HD, we speculated that FAN1
could directly interact with MMR factors at CAG repeats to
modulate expansion. To test the functional significance of the
FAN1-MLH1 interaction in an HD context, we first tested this hy-
pothesis in induced pluripotent stem cells (iPSCs) derived from a
juvenile HD patient originally carrying 125 CAGs. Immunoprecip-
itation (IP) using FAN1 antibodies showedMLH1 and PMS2were
present in FAN1 pull-down fractions, whereas MSH3 was ab-
sent, and conversely, FAN1 was present in MLH1 pull-down
fractions alongside PMS2 and MSH3 (Figure 1A). To confirm
this interaction in independent cell lines, we used HD lympho-
blastoid (LB) cells carryingmore typical, shorter, disease-associ-
ated repeat lengths (Figure 1B). To exclude antibody-specific
artifacts, we validated this interaction in U2OS cells expressing
GFP-FAN1 and confirmed that MLH1, PMS2, and MLH3 can
be detected in GFP-Trap pull-down fractions, whereas MSH2,
MSH3, and MSH6 were absent (Figure 1C). Finally, to demon-
strate the significance of this interaction in vivo, we showed
that FAN1 and MLH1 interact in cortical extracts of zQ175 and
R6/2 HD mice (Figure 1D).
To further dissect the interaction between FAN1 and the
MLH1-PMS2 heterodimer, we performed crosslinking IP masson with MLH1 and its effect on CAG stabilization activity
mponents MLH1 and PMS2. Note that MSH3 is absent from the anti-FAN1 IP
LH1 (n = 3 biological replicates).
s with MutL components, but not MutS components or PCNA (proliferating cell
ity of the pull-down (n = 4 biological replicates).
N1 interacts with MLH1. Observations were also confirmed in R6/2 HD mice at
ates).
293T cells and HD lymphoblasts. Grey parts on the proteins are structurally
protein; green line, crosslinks close to the SPYFmotif. See also Figure S1A and
f UBZ null (C44A/C47A) and nuclease null (D960A) mutations are also outlined.
ain; TPR, tetratricopeptide repeat domain; VRR_NUC, virus-type replication-
n constructs. FAN1D73–349 (highlighted in bold) did not interact with MLH1. Note
espectively) does not affect FAN1-MLH1 interaction (n = 3 biological replicates).
1–349 is sufficient to interact with MLH1 (n = 4 biological replicates).
howing lower viability when FAN1 lacks an intact nuclease domain (n = 5–8
luding mutations within key functional domains (UBZ, C44A/C47A; VRR_NUC,
essing FAN1FL but does not equate to FAN1/ (mean ±SEM, n = 2–5 biological
OVA with false discovery rate [FDR] correction of 5%). ***p < 0.001; ns, non-
CAG repeat in U2OS cells expressing FAN1 constructs over 6 weeks in culture
9 (individual data points shown) expand at a rate between that of FAN1FL or
onfidence interval [CI] in shaded areas, n = 2–5 biological replicates, n = 3–6
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OPEN ACCESSspectrometry (xIP-MS) experiments using HEK293T cells, ex-
pressing myc-tagged FAN1 and LB cells expressing endoge-
nous FAN1. As expected, we observed interactions between
FAN1 and its known FA-complex interactors, FANCD2 and
FANCI (Figure S1A; Table S1; MacKay et al., 2010; Smogorzew-
ska et al., 2010). Interestingly, analysis of the aggregated cross-
linking data from both experiments showed multiple proximity
areas between FAN1, MLH1, and PMS2, but not MLH3 (Fig-
ure 1E; Table S1). Three crosslinks were observed between
FAN1 and MLH1, two in the N-terminal part of FAN1 and one
in the TPR (tetratricopeptide repeat) domain.We found six cross-
links between FAN1 and PMS2, including four in the N-terminal
region of FAN1, one in the TPR domain, and one adjacent to
the TPR domain (Figure 1E). Intriguingly, a cluster of four cross-
links between N-terminal FAN1 (p.120-168) and both PMS2 and
MLH1 was observed. One of the FAN1 intra-protein crosslinks
(K539-S646) was in the structured region of the protein (4RID)
at a distance of 27 Å, which is consistent with the maximal dis-
tance for the crosslinker used, while all other crosslinks involve
unstructured regions with no atomic coordinates present in the
Protein Data Bank (PDB). Together, these data show that MutLa,
but not MSH3, directly interacts with FAN1 and point to specific
contact areas that could be critical for this interaction.
The FAN1 N-terminal region (p.73-349) mediates its
interaction with MLH1 and its effect on CAG
stabilization activity
To pinpoint theMLH1-binding region(s) of FAN1, we expressed a
series of GFP-tagged FAN1 deletion constructs (Figure 1F) in a
well-characterized U2OS cell model stably expressing mutant
HTT (mHTT) exon 1 (Goold et al., 2019). GFP pull-down fractions
from cell extracts expressing a FAN1 construct comprising the
first 349 residues (FAN11–349) contained levels of MLH1 similar
to those produced using full-length FAN1 (FAN1FL) (Figures 1G
and S1B). In contrast, FAN1D73–349, a deletion construct missing
most of this N-terminal region but retaining the nuclear localiza-
tion signal (NLS; p.11-25), the ubiquitin-binding zinc-finger
domain (UBZ), SAP, TPR, and nuclease domains (Zhao et al.,
2014), did not form a complex with MLH1 (Figure 1G). The inter-
action of the N terminus of FAN1 with MLH1 was confirmed by
reverse IP using MLH1 antibodies. This showed FAN1FL and
FAN11–349 bind MLH1 (Figure 1H). It is also worth noting that
PMS2 partitions with MLH1 in IP fractions derived from FAN1
knockout (FAN1/), FAN1FL, and FAN11–349 cells, indicating
FAN1 does not influence the MutLa complex interaction.
To exclude the possibility that deleting a large section of the
FAN1 sequence creates an inactive form of the protein that is
unable to bind MLH1 because it is misfolded or mis-localized,
we performed functional analyses. Live-cell imaging using the
FAN1 GFP tag showed exclusively nuclear localization (Fig-
ure S1C). Mitomycin C (MMC) stimulates the formation of nu-
clear FAN1 repair foci in a manner mediated by the UBZ domain
and requires FAN1 nuclease activity for ICL repair and survival
(MacKay et al., 2010; Smogorzewska et al., 2010). In MMC
cell viability assays, as expected, FAN11–349 was present exclu-
sively in the nucleus and formed DNA repair foci, though not as
efficiently as the full-length protein, as it lacks the DNA-binding
SAP domain, and it provided no protection against MMC4 Cell Reports 36, 109649, August 31, 2021toxicity (Figures 1I and S1C–S1E). In turn, FAN1D73–349 formed
repair foci and protected against MMC genotoxicity, indicating
that this protein was functional in ICL repair and is therefore un-
likely to be misfolded (Figures 1I and S1C–S1E). Thus, the
MLH1-binding capacity of these constructs likely reflects the
protein’s biological activity rather than mis-localization or mis-
folding. These data also suggest that the UBZ domain and
nuclease activity are not required for the FAN1-MLH1 interac-
tion. To confirm this independently, we expressed the
p.C44A/C47A and p.D960A FAN1 mutants, deficient in ubiqui-
tin-binding and nuclease activity, respectively, in U2OS cells
and assessed their MLH1-binding capacity using GFP-Trap
pull-down assays. Both constructs bound to MLH1 (Figure 1G),
and cells expressing these constructs also displayed the ex-
pected response to MMC treatment with the p.D960A, but not
the p.C44A/C47A variant showing reduced viability (Figures 1I
and S1C–S1E).
To assess the effect of the FAN1-MLH1 interaction on CAG
repeat instability, we measured CAG repeat expansion over
40 days in isogenic U2OS cells expressing each construct. Intro-
ducing the nuclease-deficient p.D960A and p.C44A/C47A UBZ
mutations into FAN1FL did not affect the stabilization of the
CAG repeat (Figure 1J). FAN11–349 was also able to stabilize
the CAG repeat, with a similar expansion rate as FAN1FL (Figures
1J, 1K, and 1L), but FAN1D73–349, the inverse construct lacking
most of the N-terminal region, did not slow CAG expansion as
effectively (Figures 1J, 1K, and 1M). Importantly, the expansion
rate in FAN1D73–349 cells was not as fast as FAN1/ cells, sug-
gesting that a FAN1 region outside of residues 73–349 also con-
tributes to CAG repeat stabilization activity.
Taken together, these structure-function analyses show that
the FAN173–349 N-terminal region is necessary and sufficient
for interaction with MLH1 and protection against CAG expan-
sion, independent of UBZ and nuclease activity.
The FAN1 126SPYF129 domain mediates MLH1
interaction and confers CAG repeat stabilization in
conjunction with FAN1 nuclease activity
We observed that FAN11–165 and FAN11–190 constructs both
bind MLH1 robustly, but FAN11–140 showed a reduced interac-
tion (Figure 2A). Quantification of GFP-Trap pull-down fractions
suggestedMLH1 binding increased as the FAN1N-terminal con-
structs lengthen, whereas FAN11–120 and the deletion construct
FAN1D120–140 showed little or no MLH1 binding (Figures 2A–2C).
Therefore, MLH1 binding absolutely requires FAN1 residues
120–140, but downstream sequences could contribute to com-
plex stability. These data are consistent with on-bead crosslink-
ing experiments that showed close associations betweenMLH1-
PMS2 and the N-terminal region of FAN1 (Figure 1E).
The N-terminal region of FAN1 is largely unstructured and rela-
tively nonconserved. It does, however, contain three highly
conserved regions, the first of which consists of a SPYF motif
(p.126-129; Figure 2D) similar to the MLH1-interacting peptide
box (MIP-box) found in many of MLH1’s interaction partners
(Dherin et al., 2009; Iyer et al., 2010). Considering the similarity
to a knownMLH1-binding sequence and the data from our struc-
ture-function analysis, we explored the role of 126SPYF129 in the
FAN1-MLH1 interaction. We introduced a series of alanine
Figure 2. A conserved SPYFmotif in FAN1 is
required for MLH1 binding
(A–C) CoIP extracts using GFP-Trap beads in
U2OS cells expressing truncated FAN1 constructs
(A and B) with quantification showing progressively
longer FAN1 N-terminal fragments bind more
MLH1 (C). Note residues 120–140 are essential for
MLH1 binding (mean ± SEM, n = 4–5 biological
replicates, F(5,22) = 88.31, p < 0.001 by one-way
ANOVA with FDR correction of 5%). *p < 0.05;
***p < 0.001; ns, non-significant.
(D) Conservation analysis schematic showing
SPYF motif is heavily conserved within common
model species (residues with >80% consensus
shown in yellow).
(E) Schematic illustrating FAN1 constructs with
mutations at conserved SPYF residues that were
cloned into the U2OS system. Nuclease null mu-
tation (D960A) is also outlined. UBZ, ubiquitin-
binding zinc-finger domain; SAP, SAF-A/B, Acinus
and PIAS domain; TPR, tetratricopeptide repeat
domain; VRR_NUC, virus-type replication-repair
nuclease domain.
(F) MMC viability curves in U2OS cells expressing
FAN1 SPYF mutants (mean ± SD). Note viability is
only reduced in FAN1/ line (n = 6–8 biological
replicates, n = 3 technical replicates) (see also
Figure S1G).
(G and H) Input and GFP-Trap pull-down fractions
from U2OS cell extracts expressing FAN1 SPYF
mutants (G) with quantification (H) showing
reduced MLH1-binding with mutation of SPYF
motif relative to FL construct. Q123A is displayed
as a control, having a mutation outside the
conserved motif (mean ± SEM, n = 5 biological
replicates; F(4,17) = 744.6, p < 0.001 by one-way
ANOVA with FDR correction of 5%). ***p < 0.001.
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esis and expressed these mutants as GFP fusion proteins in
U2OS cells (Figure 2E). Importantly, cells expressing these con-
structs were protected against MMC toxicity and formed nuclear
repair foci normally, suggesting the SPYF mutations did not
affect ICL repair activity (Figures 2F, S1C, S1F, and S1G).
Instead, GFP-Trap pull-down fractions showed residues within
the SPYF motif, in particular the aromatic residues Y128 and
F129, as critical for MLH1 binding, whereas mutation of a well-
conserved residue outside this sequence (Q123) did not affect
binding (Figures 2G and 2H). These data agree closely with our
structure-function analysis and demonstrate that FAN1 interacts
with MLH1 through its conserved N-terminal SPYF motif.C
Mutations S126A, Y128A, and F129A
within the SPYF motif reduced the stabili-
zation activity of FAN1, with substitution
of the aromatic residues exhibiting the
greatest increase in the CAG repeat
expansion rate, while Q123A had no
effect (Figure 3A). Similarly, FAN11–120
did not stabilize the CAG repeat,
while longer SPYF-motif-containing con-
structs, including FAN11–165, significantlyrestrained CAG expansion (Figure 3B). Consistent with this, de-
leting residues 120–140 (FAN1D120–140) from the FAN11–349
construct reduced the stabilization activity (Figure 3B). As for
the SPYF mutants, CAG repeat stabilization activity and
MLH1-binding correlate closely, indicating they are mechanisti-
cally linked.
Mutation of the SPYF motif was associated with an increased
expansion rate relative to FAN1FL, significant because it shows
nuclease function alone does not fully stabilize the CAG repeat,
as FAN1FL and SPYF mutants have similar ICL repair activity
(Figures 2F, S1C, S1F, and S1G). Despite this, we observed
that the expansion rate in SPYF-deficient constructs was not
as fast as in FAN1/ cells (Figure 3A). In fact, the stabilizationell Reports 36, 109649, August 31, 2021 5
Figure 3. FAN1 SPYFmotif and nuclease ac-
tivity stabilize the HTT CAG repeat
(A) CAG expansion rates in U2OS cells expressing
FAN1 constructs with mutations at conserved
SPYF motif. Note that mutation of this domain re-
sults in hastened expansion of the HTT CAG
repeat. Q123A is displayed as a control, having a
mutation outside the conserved motif. (mean ±
SEM, n = 2–5 biological replicates, n = 3–6 tech-
nical replicates, F(5,83) = 28.64, p < 0.001 by one-
way ANOVA with FDR correction of 5%). **p <
0.01, ***p < 0.001, ns = non-significant.
(B) CAG expansion rates in U2OS cells expressing
truncated N-terminal constructs of FAN1, showing
residues 120–140 contribute significantly to HTT
CAG repeat stability. (mean ± SEM, n = 2–5 bio-
logical replicates, n = 3–6 technical replicates,
F(5,86) = 22.38, p < 0.001 by one-way ANOVA with
FDR correction of 5%). *p < 0.05, ***p < 0.001, ns =
non-significant.
(C) Input and GFP-Trap pull-down fractions
from U2OS cell extracts expressing FAN1FL and
FAN1F129A/D960A showing reduced MLH1-binding
with mutation of SPYF motif relative to FL. Note
equivalent FAN1FL and FAN1F129A/D960A expres-
sion (n = 2 biological replicates).
(D) MMC viability curves in U2OS cells expressing
FAN1F129A and FAN1F129A/D960A mutants (mean ±
SD, n = 6–7 biological replicates, n = 3 technical
replicates). Note resistance to MMC toxicity is only
maintained in the F129A line. See also Figure S1H.
(E–G) Fragment analysis traces illustrating expan-
sionof the exogenousHTT 118CAG repeat inU2OS
cells expressing FAN1F129A or FAN1F129A/D960A mu-
tants over 6 weeks in culture with time courses
plotted (F; mean± SD, 95%CI in shaded areas) and
quantified (G). Cells expressing FAN1F129A/D960A
show equivalent expansion as FAN1/ cells (mean
± SEM, n = 2–5 biological replicates, n = 3–6 tech-
nical replicates, F(3,72) = 39.27, p < 0.001 by one-
way ANOVA with FDR correction of 5%). **p < 0.01;
***p < 0.001; ns, non-significant.
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OPEN ACCESSactivity of the SPYF mutants was similar to that shown by
FAN1D73–349, suggesting there is residual stabilization activity
downstream of p.349, with the most likely candidate being the
nuclease domain. To assess this, we introduced the nuclease-
deficient p.D960A mutation into a SPYF-deficient construct
(FAN1F129A). Immunoblots demonstrated that FAN1F129A/D960A
and FAN1FL were expressed at similar levels (Figure 3C),
and FAN1F129A/D960A was able to form DNA repair foci in
response to MMC, a response requiring a functional UBZ
domain (Figures S1C and S1F). However, as expected, GFP-
Trap pull-down experiments demonstrated reducedMLH1 bind-
ing, while decreased MMC viability showed deficient ICL repair
(Figures 3C, 3D, and S1H). Importantly, repeat expansion in
FAN1F129A/D960A cells was faster than the F129A single mutant
and equivalent to FAN1/ cells (Figures 3E–3G).
Taken together, these data show that the FAN1 SPYF motif
mediates its MLH1 interaction and that FAN1’s protective stabi-
lization of the CAG repeat involves MLH1 binding and the
nuclease domain.6 Cell Reports 36, 109649, August 31, 2021FAN1 regulates MMR activity by competing with MSH3
for MLH1 binding
Consistent with reduced MMR activity, MLH1 and MSH3
knockout abolishes repeat expansion (Figures 4A–4C) and in
the case of MLH1 increases resistance to 6-thioguanine (6TG)
(Figures 4D and S2A; Swann et al., 1996). Surprisingly, we
observed that expression of FAN1FL or FAN11–349 in an MLH1WT
background also increases 6TG resistance relative to FAN1/
cells, whereas expression of FAN1D73–349 or SPYF mutants
had no effect (Figures 4D and S2A–S2C). This suggested that
the SPYF motif sequesters MLH1 away from its other binding
partners, reducing MMR activity and ultimately preventing
repeat expansion. To explore this possibility, we tested the abil-
ity of MLH1 to associate with MSH3 in the presence or absence
of FAN1. This is of particular significance, given the key role of
MSH3 in somatic expansion (Figures 4B and 4C) and the similar-
ity of the FAN1 SPYF motif to the MIP-box in MSH3, which me-
diates binding to MLH1. Consistent with this, MSH3 pull-downs
showed that MLH1 levels were reduced in FAN1FL samples
Figure 4. FAN1 regulates mismatch repair
(MMR) activity through MLH1 binding
(A and B) Western blots showing MMR protein
expression in U2OS MLH1 (A) and MSH3 (B)
knockout lines (n = 3 biological replicates).
(C) CAG expansion rates in FAN1/, MLH1/,
and MSH3/ U2OS cell lines. Note that knockout
of MSH3 or MLH1 ablates CAG repeat expansion
(mean ± SEM, n = 2–5 biological replicates, n = 3–
6 technical replicates, F(2,72) = 272.5, p < 0.001 by
one-way ANOVA with FDR correction of 5%).
***p < 0.001; ns, non-significant.
(D) 6TG viability curves in U2OS cells expressing
FAN1 constructs and MLH1, showing cells with an
intact FAN1 SPYFmotif have enhanced resistance
to 6TG, indicating reduced MMR activity.
MLH1/ cells serve as a control (mean ±SD, n = 5
biological replicates, n = 3 technical replicates).
See also Figure S2A.
(E) CoIP of MLH1 and binding partners from
FAN1/ and FAN1FL cells. Note FAN1 expression
reduces MSH3 levels in MLH1 IP fractions but
does not affect PMS2 (n = 4 biological replicates).
See also Figure S2F.
(F) CoIP of MLH1 and binding partners from 125
CAG HD MSNs with shRNA-mediated FAN1
knockdown. Untreated cells and an empty shRNA
vector were used as controls. Note that FAN1
knockdown increases MSH3 levels in MLH1 IP
fractions (n = 3 biological replicates). See also
Figures S2G and S2H.
(G) CoIP of myc-tagged FAN1 from HEK293T cells
expressing strep-tagged MLH1 variants and
endogenous MLH1. Note endogenous MLH1 and
strep-tagged MLH1FL bind to FAN1, whereas
MLH1E669A does not (n = 2 biological replicates).
(H) FAN1 peptide competition assay in HeLa cell
nuclear extracts showing FAN1 wild-type (wt)
60-mer peptides (15 mM) reducing MLH1-MSH3
interactions, whereas FAN1 mutant (mut.) pep-
tides do not (n = 3 biological replicates).
(I) ChIP extracts from FAN1FL and FAN1/ U2OS
cells, immunoprecipitated with aMLH1 antibodies
and DNA amplified with primers targeting HTT
CAG repeat region. Note the decreased levels of
both long (exogenous HTT) and short (endoge-
nous HTT) amplicons in FL ChIP fractions (n = 3
biological replicates).
(J) Fragment analysis traces from U2OS FAN1/
extracts show the presence of the CAG repeat
from the endogenous HTT allele (20 CAG units)
and the longer exogenous repeat (118 CAG) from the exon 1 construct in both input and ChIP fractions. The lack of signal in the control IP (-Ab) shows the
specificity of the procedure (n = 3 biological replicates, n = 3 technical replicates).
(K) Quantification of DNA levels in ChIP fractions from FL and FAN1/ U2OS cells. Primer pairs proximal to the CAG repeat (P1 and P2) and toward the 30 end of
HTT (HTT2) were used (mean ± SEM, n = 3 biological replicates, n = 3 technical replicates; P1: F(2,6) = 20.76, p = 0.002; P2: F(2,6) = 17.84, p = 0.003; HTT2:
F(2,6) = 23.56, p = 0.001 by one-way ANOVA with FDR correction of 5%). *p < 0.05; ***p < 0.001.
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OPEN ACCESSrelative to FAN1/ (Figures S2D and S2E). FAN1 was not
observed in these IPs, confirming it does not interact directly
with MSH3. This suggests that FAN1 controls MMR complex as-
sembly by sequestering MLH1. In MLH1 pull-downs, FAN1,
MSH3, and PMS2 were recovered. The presence of FAN1 did
not affect PMS2 levels, suggesting it does not interfere with
MutLa complexing, but MSH3 levels were reduced in FAN1FL
relative to FAN1/ samples (Figures 4E and S2F). Thus, FAN1expression reduces the MLH1-MSH3 interaction. To show this
relationship exists in cells expressing endogenous proteins, we
knocked down FAN1 expression in HD iPSCs carrying 125
CAGs. Stable incorporation of small hairpin RNA (shRNA) target-
ing FAN1 reduced FAN1 protein levels by 90%–95% (Fig-
ure S2G), and medium spiny neurons (MSNs) derived from these
cells show increased CAG repeat expansion rate relative to con-
trol cells (data not shown). MLH1 IPs from MSN extracts showCell Reports 36, 109649, August 31, 2021 7
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the IP fractions relative to the control cells (Figures 4F and
S2H). Thus, we conclude that like in U2OS cells, FAN1 expres-
sion reduces the MLH1-MSH3 interaction in HD MSNs.
The MLH1 MIP-box-interacting (S2) site contains several key
residues spread across the C-terminal domain. Mutation of
one of these, E669, in the human sequence has been shown to
disrupt MLH1 MIP-box interactions but leave MutL complex for-
mation unaffected (Dherin et al., 2009; Iyer et al., 2010). In the
U2OS system, myc-tagged FAN1FL binds strep-tagged MLH1
with wild-type (WT) sequence, but not the E669A mutant (Fig-
ure 4G), indicating the SPYF motif acts as a canonical MIP-
box. This supports our finding that FAN1 competes with MSH3
for the MLH1 S2 interaction site. Incubating HeLa nuclear ex-
tracts with a synthetic 60-mer FAN1 WT peptide surrounding
the SPYF motif reduced the levels of MSH3 co-immunoprecipi-
tating with MLH1 in a dose-dependent manner (Figures 4H and
S2I). Critically, peptides in which the MLH1 interaction site is
mutated did not affect the MLH1-MSH3 interaction (Figure 4H).
Taken together, our data support a model where FAN1 com-
petes with MSH3 for binding the MIP-box-interacting S2 domain
of MLH1. In human striatum and cortex, MLH1 and FAN1 are ex-
pressed at similar levels, both higher than the levels of MSH3
(Figure S3A), indicating FAN1 could be a major regulator of
MLH1-MSH3 interactions in vivo.
One consequence of this may be a reduction of MSH3-depen-
dent MLH1 recruitment to the CAG repeat. To assess this, we
performed a chromatin IP (ChIP) assay, involving anti-MLH1 IP
from FAN1/ and FAN1FL U2OS cells. PCR across the HTT
CAG repeat identified the endogenous 20 CAG (‘‘short’’) and
exogenous 118 CAG repeat (‘‘long’’) in both samples (Figure 4I).
The presence of long and short repeat sequenceswas confirmed
by fragment analysis of the ChIP samples (Figure 4J). qRT-PCR
analysis showed there was less HTT CAG DNA in anti-MLH1
ChIP fractions from FAN1FL cells relative to FAN1/ (Figure 4K).
This is consistent with FAN1 reducing MLH1’s interaction with
the CAG repeat.
To further explore the role of DNA repair genes implicated in
somatic instability, we analyzed FAN1/, FAN1FL, MLH1/,
and MSH3/ U2OS cell lines for evidence of microsatellite
instability (MSI) over the course of our CAG repeat expansion
assays.
MutSb deficiency results in MSI at tetra- and dinucleotide re-
peats, whereas MutSa deficiency causes MSI at mono- and
dinucleotide repeats (Carethers, 2017). Although MLH1/ cells
did not demonstrate CAG repeat expansion (Figure 4C), there
was instability at tetranucleotide marker D20S85 (otherwise
known as EMAST, or elevated microsatellite alterations at
selected tetranucleotide repeats), indicating MMR deficiency
(Figure S3B). Similarly, MSH3/ cells showed MSI at several
tetranucleotide (MYCL1, D9S242, D20S82, and D20S85) and
dinucleotide loci (D8S321), indicating MutSb deficiency, but
the CAG repeat remained stable (Figures 4B, 4C, and S3B).
Manipulation of FAN1 did not affect MSI in the time course of
the assay (Figure S3B). Collectively, these data suggest that
FAN1 suppresses MMR activity by sequestering MLH1 away
from MSH3, thus preventing error-prone repair and CAG repeat
expansion.8 Cell Reports 36, 109649, August 31, 2021DISCUSSION
Recent genetic studies have shown somatic expansion of the
CAG repeat is the key pathogenic process driving HD onset
and progression. In this study, we investigated the interaction
of the HD genetic modifiers FAN1 and MLH1 and their role in
repeat instability in patient-derived cells, HD mouse models,
and a U2OS cell system stably expressing mHTT exon 1. We
demonstrated that a FAN1 SPYF motif (p.126-129) mediates its
binding to MLH1 and that this interaction protects against CAG
repeat expansion. We also demonstrated the nuclease domain
of FAN1 is involved in the protective effects of FAN1.
FAN1 N-terminal deletion constructs lacking the SPYF motif
fail to stabilize the CAG repeat; FAN11–120 accelerates repeat
expansion to the same rate as FAN1/, whereas longer con-
structs containing the SPYF motif, including FAN11–165, slow
the expansion rate significantly. Consistent with this, deleting
residues 120–140 (FAN1D120–140) from the FAN11–349 construct
reduces stabilization activity. SPYF mutations reduce FAN1-
MLH1 binding and accelerate repeat expansion. MLH1 binding,
and CAG stabilization activity correlate closely, indicating they
are mechanistically linked (Figures 2 and 3). The homology be-
tween the FAN1 SPYF andMSH3MIP-box supports our hypoth-
esis of competition for MLH1 binding. A MIP-box is found in
several MLH1 interaction partners, including MSH3, EXO1, and
NTG2, and it has been shown to interact with the C-terminal
S2 site ofMLH1, a region comprising several conserved residues
(Dherin et al., 2009; Iyer et al., 2010). Our crosslinking results
show that interactions between the FAN1 SPYF motif and
MLH1 are clustered at the unstructured central domain of
MLH1 and include crosslinks consistent with an interaction
near the S2 site. Introducing the E669A mutation into the S2
site of MLH1 abrogates FAN1 interaction, suggesting the SPYF
motif indeed acts as a MIP-box. FAN1 binding would therefore
sterically inhibit MLH1’s interaction with MSH3 and modulate
MutSb-driven MMR activity. The close associations among
FAN1, MLH1, and PMS2 demonstrate that FAN1 interacts func-
tionally with the MutLa complex. CoIP shows MLH3 also associ-
ates with FAN1 in U2OS cell extracts, suggesting the MutLg
complex may also interact with FAN1.
Consistent with previous data from mouse models, we find
that MLH1 or MSH3 knockout prevents CAG repeat expansion
(Figures 4A–4C), showing the absolute requirement of MutSb-
driven MMR for this process (Loupe et al., 2020; Pinto et al.,
2013; Tomé et al., 2013). Our data suggest that FAN1 competes
with MSH3 for MutLa (or MutLg) binding, preventing MMR-
driven CAG expansion. The potential significance to HD is shown
by the inhibitory effect of FAN1 expression on MLH1-MSH3 in-
teractions in HD MSNs and the similar expression levels of
MLH1 and FAN1 in human cortex and striatum, meaning FAN1
could be a major regulator of MLH1-MSH3 interactions in vivo.
Cells defective in MMR are resistant to 6TG toxicity and
display MSI (Swann et al., 1996). MLH1/ U2OS cells are resis-
tant to 6TG and show instability at an EMAST locus in the
genome (Figures 4D, S2A, and S3B), indicating they have dysre-
gulated MMR activity. Interestingly, cells overexpressing FAN1
with an active SPYF domain showed significantly increased
resistance to 6TG, as compared to FAN1/ cells (Figures 4D
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OPEN ACCESSand S2A–S2C). These cells did not show alterations at EMAST
loci, which likely reflects the partial inhibition of MMR activity
and the relatively short time course of the assay. Importantly,
FAN1 constructs lacking an active SPYF motif did not protect
against 6TG toxicity, showing that MLH1-binding likely underlies
FAN1’s regulation of MMR activity. This is interesting as it sug-
gests FAN1 may be modulating both MutSa- and MutSb-driven
MMR activity (Stojic et al., 2004). Our data show that FAN1 se-
questers MLH1 and prevents interaction with MSH3 by
competing for the MIP-box-binding S2 site (Figures 4G and
4H). The lack of MSH2 and MSH6 in anti-FAN1 IP fractions con-
firms earlier reports that these proteins do not directly interact
(MacKay et al., 2010; Smogorzewska et al., 2010) and suggests
a similar mechanism may operate to regulate MutSa-MLH1 in-
teractions. MMR interactions with the FA pathway and FAN1 it-
self have been reported previously (Peng et al., 2014; Williams
et al., 2011; Rikitake et al., 2020), but direct inhibition of MMR,
mediated by MLH1 sequestration, has not. The physiological
significance of these findings needs further inquiry, but it is
evident from experiments in mouse models that FAN1 and
MLH1 interact genetically and play a crucial role in regulating so-
matic expansion, likely bymodulatingMMR activity (Loupe et al.,
2020).
Our data also indicate that the FAN1 nuclease domain contrib-
utes to its repeat stabilization activity, in accordance with
recent data in preprint on bioRxiv (McAllister et al., 2021). The
FAN1F129A/ D960A SPYF and nuclease double mutant demon-
strated that FAN1-MLH1 binding and nuclease activity have in-
dependent, but additive, repeat-stabilizing effects. Though the
p.D960A nuclease inactivation alone did not affect repeat insta-
bility (Goold et al., 2019; Figure 1J), the overexpression of FAN1
mutants in U2OS cells likely masked the subtle contribution of
the nuclease domain by sequestering most available MLH1
and shutting down error-prone MMR. In the absence of this
dominant activity, for example following SPYF mutation, the sta-
bilization activity of the nuclease domain can be observed. In this
scenario, FAN1’s nuclease activity could operate downstream of
MSH3-mediated recruitment of MLH1, regulating the repair pro-
cess to reduce errant CAG incorporation, possibly by acting
directly on the DNA. This proposal is supported by data showing
FAN1 binds directly to CAG repeat DNA (Goold et al., 2019; Kim
et al., 2020). Our data also suggest an intact FAN1 UBZ domain
is not required to stabilize the CAG repeat. Mutations that inac-
tivate ubiquitin binding do not affect the expansion rate but pre-
vent recruitment to DNA repair foci induced by MMC treatment.
This indicates recruitment by the ID2 FA complex is not required
for stabilization.
Limitations of the study and future directions
Further studies are needed to establish the processes modu-
lating the FAN1-MLH1 interaction. For instance, our FAN1 struc-
ture-function analyses were performed using cells overexpress-
ing exogenous FAN1. It will be important to confirm these
interactions in the context of endogenous FAN1 in human cells
and by creating FAN1 mouse models. Moreover, the precise
requirement for the FAN1 nuclease activity in this model will
need to be (re)assessed in more detail. It is compelling to spec-
ulate that, as for EXO1 (Guan et al., 2021), MLH1 could directlyregulate FAN1 nuclease activity to promote DNA resection.
A greater understanding of such processes will also be critical
for the development of new therapies.
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OPEN ACCESSSTAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
FAN1 sheep polyclonal (human) CHDI Foundation N/A
FAN1 sheep polyclonal (mouse) MRC-PPU reagents S101D
MLH1 mouse monoclonal (human) BD Biosciences 554073: RRID:AB_395227
MSH3 mouse monoclonal BD Biosciences 611390; RRID:AB_398912
MSH2 rabbit Cell Signaling Technology 2017;RRID:AB_2235387
MSH6 mouse monoclonal BD Biosciences 610918;RRID:AB_398233
MLH1 mouse monoclonal (human/mouse) Abcam ab92312;RRID:AB_2049968
PMS2 Santa Cruz Biotechnology sc-25315; RRID:AB_628163
MLH3 Santa Cruz Biotechnology sc-25313; RRID:AB_627954
PCNA Cell Signaling Technology 13110; RRID:AB_2636979
GAPDH Santa Cruz Biotechnology sc-32233; RRID:AB_627679
GFP Santa Cruz Biotechnology sc-9996; RRID:AB_627695
Bacterial and virus strains
One Shot TOP10 E. coli ThermoFisher C4040
Chemicals, peptides, and recombinant proteins
FAN1 60-mer wild-type MLH1-interaction-defective
mutant peptides (amino acids 118-177)
GenScript N/A
Critical commercial assays
Thiazolyl Blue Tetrazolium Bromide (MTT) assay Sigma 34-000-1002
SYBR Green Master Mix ThermoFisher A25741
QuickChange XL kit Agilent 200516
QIAamp DNA Mini kit QIAGEN 51306
Deposited data
Mass spectrometry proteomics data ProteomeXchange PXD023221
Experimental models: Cell lines
U2OS FAN1/ cells Prof Rouse University of Dundee) N/A
iPSC 125 CAG This study N/A
HEK293T ATCC N/A
Lymphoblastoid cells This study N/A
PheonixiAmpho ATCC N/A
Experimental models: Organisms/strains
zQ175 mice Charles River N/A
R6/2 mice Envigo, Netherlands N/A
Oligonucleotides
qRT-PCR primers pair 1 forward
CCGCTCAGGTTCTGCTTTTA,
Thermo N/A
pair 1 reverse GCCTTCATCAGCTTTTCCAG Thermo N/A
pair 2 forward CCAGAGCCCCATTCATTG Thermo N/A
pair 2 reverse GCCTTCATCAGCTTTTCCAG Thermo N/A
30 HTT forward TGCCTTTCGAAGTTGATGCA, Thermo N/A
30 HTT reverse TGCCACCACGAATTTCACAA). Thermo N/A
Fragment analysis Thermo N/A
(Continued on next page)
e1 Cell Reports 36, 109649, August 31, 2021
Continued




Reverse primer: CGGCTGAGGCAGCAGCGGCTGT IDT N/A
Recombinant DNA
pcDNA5.1 FRT/TO GFP FAN1 MRC-PPU reagents DU19495
pcDNA5.1 FRT/TO GFP FAN1 deletion constructs and mutants This study N/A
Software and algorithms
GraphPad Prism 9 Software, Inc, USA https://www.graphpad.com/scientific-
software/prism/
GeneMapper v6. software ThermoFisher A38888
Fragment analysis Custom R script This study https://caginstability.ml
xQuest/xProphet xQuest N/A
Other
GFP-Trap beads ChromoTek gtma-10





Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Prof Sarah
J. Tabrizi (s.tabrizi@ucl.ac.uk).
Materials availability
iPSC 125 CAG were generated from peripheral blood mononuclear cells donated by a HD patient by reprogramming at Censo in
Edinburgh, UK. iPSCs were karyotypically stable, and whole genome sequencing of blood from the same individual and iPSCs
did not identify any clinically significant variants.
Data and code availability
d Mass spectrometry proteomics data are deposited at ProteomeXchange: PXD023221 (Username: reviewer_pxd023221@e-
bi.ac.uk - Password: lSFFWYxO).
d Fragment analysis software is available at https://caginstability.ml.
d Any additional information required to reanalyze the data reported in this work is available from the Lead Contact upon request.EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
All procedures were performed in accordance with the Animals (Scientific Procedures) Act 1986 andwere approved by the University
College London Ethical Review Process Committee. R6/2 mice were bred by backcrossing R6/2 males to C57BL/6JOlaHsd x CBA/
CaOlaHsd F1 females (B6CBAF1/OlaHsd, Envigo, Netherlands) and zQ175 mice were bred by backcrossing males to C57BL/6J fe-
males (Charles River). Mouse husbandry, health status, genotyping and CAG repeat sizing were as previously described (Landles
et al., 2020). For IP experiments, brains were from female mice. CAG size for the zQ175 was 206 (SD ± 3) and R6/2 was 182
(SD ± 1). Mice were sacrificed by a schedule 1 procedure at 6months of age (zQ175) or 12weeks of age (R6/2), brains were dissected
rapidly, tissues were snap frozen in liquid nitrogen and stored at 80C.
METHOD DETAILS
Cell culture and manipulation
U2OS FAN1/ cells were generated as previously described, featuring FRT sites introduced into the genome, enabling complemen-
tation with tetracycline-inducible FAN1 variants when co-transfected with Flp recombinase. This line was kindly gifted by Prof. John
Rouse (University of Dundee, Scotland). Introducing a lentiviralHTT exon 1 construct harboring 118 CAG repeats allows examinationCell Reports 36, 109649, August 31, 2021 e2
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OPEN ACCESSof the effects of different FAN1 activities/regions on repeat stability (Goold et al., 2019). U2OS cells were maintained in DMEM with
GlutaMAX, supplemented with 10% FBS and pen-strep. ICL repair assays were performed as described previously (Goold et al.,
2019). Cells were plated at 200 cells per well in a 96 well plate. The next day MMC was added to cells at increasing concentrations
for 16 h. Cells were washed into fresh media, cultured for 7-10 days until control cells were confluent. The proportion of live cells was
then assayed. Cell survival was expressed as a percentage of control untreated cells. For quantifying GFP-FAN1 foci, cells were
imaged using a fluorescent microscope and were considered positive with R 5 foci per nucleus.
Lymphoblastoid cells derived from the TRACK-HD cohort were cultured in RPMI medium supplemented with 15% fetal bovine
serum (FBS), 100 U/ml penicillin and 100 mg/ml streptomycin.
The shRNA hairpin targeting FAN1 (target sequence: GTAAGGCTCTTTCAACGTA) was subcloned into pSUPER.retro.Puro and
transfected into Phoenix Ampho packaging cells using Lipofectamine LTX. After 16 h, 8 mL fresh media was added. Cell media con-
taining mature retrovirus was harvested 48 h post-transfection. This was filtered and frozen at 80C or used directly.
iPSC culture and manipulation
Stem cells were maintained in Essential E8 medium (ThermoFisher) on Thermo-Nunc plasticware coated with Geltrex (GIBCO)
diluted 1:50 in DMEM/F12 without glutamine. They were passaged by manual dissociation using 0.02% EDTA (GIBCO). MSN differ-
entiation was carried out as described (32) using Activin A to direct ganglionic/striatal fate. Media containing retrovirus encoding
shRNA hairpins targeting FAN1 or empty vector was mixed one to one with normal iPSC media and supplemented with polybrene
(8 mg/ml). This media was added to iPSC at 70% confluence and the cells were incubated for 16 h. Fresh media was added to the
cells for a further 48 h prior to selection. For this, themedia was supplemented with puromycin (1 mg/ml) and the cells weremonitored
ensuring regular media changes tominimize the number of dead cells in the culture. Colonies of transduced cells were detected after
2–3 weeks. Untreated cells were cultured alongside the selected cells and used as controls in subsequent experiments.
Immunoprecipitation, ChIP, cloning, SDM and CRISPR
ChIP analysis was performedwith the EZ-Magna ChIP AChromatin Immunoprecipitation Kit according to themanufacturer’s instruc-
tions. Chromatin was fragmented by 15 cycles of 30 s sonication in a Bioruptor apparatus at 4C. Immunoprecipitation was done
overnight at 4C using anti-MLH1 antibodies (BD Biosciences). DNA from ChIP and input fractions was quantified by SYBR (Thermo,
#A25741) qRT-PCR using primers targeting two regions proximal to the CAG repeat (pair 1 forward CCGCTCAGGTTCTGCTTTTA,
reverse GCCTTCATCAGCTTTTCCAG; pair 2 forward CCAGAGCCCCATTCATTG, reverse GCCTTCATCAGCTTTTCCAG), and one
distal, at the 30 end of HTT (forward TGCCTTTCGAAGTTGATGCA, reverse TGCCACCACGAATTTCACAA). DNA levels were quan-
tified relative to a genomic DNA standard. Results were expressed as percentage of the DNA levels in U2OS FAN1/ChIP fractions.
Cell extracts were prepared for SDS-polyacrylamide gel electrophoresis (PAGE) as described previously (Goold et al., 2011). Cells
were detached by trypsinisation, washed in media and centrifuged at 300 g for 5 min. Cell pellets were resuspended in PBS, trans-
ferred to 1.5 mL eppendorfs and centrifuged at 10,000 g for 1 min. Cell pellets were resuspended in IP buffer (20 mm Tris, pH 7.4,
150 mmNaCl, 1 mm EDTA, 1% Triton X-100 supplemented with Benzonase 2 U/ml and protease inhibitors) and incubated on ice for
20 min. Protein concentrations in the lysates were determined by Bio-Rad assay. Proteins were precipitated with cold methanol and
resuspended in SDS sample buffer to 2 mg/ml. The antibodies used were a FAN1 sheep polyclonal antibody (Goold et al., 2019);
MSH3 or MLH1 monoclonal antibodies (BD Biosciences, UK); PCNA and MSH2 (Cell Signaling Technology, Danvers, MA, USA);
and PMS2, GAPDH and GFP rabbit polyclonal antibodies (Santa Cruz Biotechnology, Dallas, TX, USA). To analyze mouse cortex
samples antibodies to FAN1 (sheep polyclonal S101D, available from DundeeMRC PP) andMLH1 (Abcam) were used. Immunoblots
were quantified with the Odyssey CLx Imaging System, (Lincoln, NE, USA) using Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), p38 MAP kinase and b-actin as loading controls. For immunoprecipitation (IP) analysis, washed cells were resuspended
in IP buffer and incubated on ice for 20 min. The cell extracts were centrifuged at 10,000 g for 2 min and the supernatant fraction was
used as input. Mouse cortex was homogenized in modified RIPA buffer (50mM Tris pH 7.4, 1mM EDTA, 1% Tx100, 0.5% sodium
deoxycholate and 0.1% SDS supplemented with Benzonase 2 U/ml and protease inhibitors) and incubated on ice for 20 min. The
sample was clarified by centrifugation at 20,000 g for 10 min at 4C. Extracts were diluted 1 to 10 with IP buffer and used as input.
GFP-Trap beads or FAN1 sheep polyclonal and MSH3 or MLH1 monoclonal antibodies and protein G magnetic beads were used to
capture protein complexes. Beads were washed 3 times in IP buffer and eluted by heating in SDS sample buffer.
Peptide competition assay
Custom-designed FAN1 60-mer wild-type and MLH1-interaction-defective mutant peptides (amino acids 118-177) were purchased
from GenScript (A.P., unpublished data). 1 mg of HeLa nuclear extracts were incubated with or without peptides in 0.5 mL NP40
buffer for 2 h at 4C with rotation. 1 mg of anti-MLH1 rabbit monoclonal antibody (D38G9, Cell Signaling) was added to the samples
and incubated overnight at 4C with rotation. Protein A-Sepharose beads (CL4B Sigma) were equilibrated in NP40 buffer and 25 ml
bead slurry were then added to each sample and incubated for 2 h at 4Cwith rotation. The beads were then washed three times with
NP40 buffer and once with 1xTEN100 buffer, boiled in SDS sample buffer and analyzed by western blotting using anti-MSH3 (H300,
sc-11441, Santa Cruz), anti-PMS2 (B3, sc-25315, Santa Cruz) and anti-MLH1 (ab92312, Abcam) antibodies.
FAN1 point mutations were generated by site-directedmutagenesis using theQuickChange XL kit according to themanufacturer’s
instructions (Agilent, CA, USA). The presence of the DNA base changes was confirmed by sequencing of the genomic DNA isolatede3 Cell Reports 36, 109649, August 31, 2021
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OPEN ACCESSfrom reconstituted cells. Deletion constructs were synthesized by GeneArt (Thermo Fisher) and subcloned into pcDNA5.1 FRT/TO
GFP FAN1 using BamH1, EcoRV and Not1 restriction sites. A biscistronic vector encoding myc-tagged FAN1 downstream of a strep
tagged MLH1 and separated by a P2A sequence was generated. The E669A substitution was generated by SDM. CRISPR guide
sequences encoded in pX458 vector were used to inactivate the MSH3 and MLH1 genes in U2OS cells. Knockout was confirmed
by western blot, sequencing and functional assays.
Somatic instability assay
DNA was extracted from samples by the QIAamp DNA Mini kit (QIAGEN, #51306) and the HTT locus amplified by PCR (6-FAM-
labeled F. primer: AAGGCCTTCGAGTCCCTCAAGTCCTT; R. primer: CGGCTGAGGCAGCAGCGGCTGT). The PCRproduct was de-
natured and analyzed by capillary electrophoresis, on an Applied Bioscience 3730XL DNA Analyzer (Thermo). Chromatographs were
aligned in GeneMapper v6. software (Thermo). To calculate modal CAG repeat length and instability index, GeneMapper data was
exported and analyzed with a custom R script, available at https://caginstability.ml with an inclusion threshold of 20% of modal peak
height and manually confirmed.
Microsatellite instability (MSI) analysis
DNA from ChIP samples was amplified in parallel by fluorescently labeled PCR at unstable tetranucleotide (D8S321, D20S82,
D9S242, MYCL1, D20S85), dinucleotide (D2S123, D5S346, D17S250, D18S64, D18S69), mononucleotide (NR-21, NR-24, BAT-
25, BAT-26, MONO-27, NR-27) and stable control pentanucleotide (Penta C and Penta D) loci. Fluorescently labeled fragments
were separated by capillary electrophoresis and the repeat length of each allele determined with a custom R script, as above.
Transcriptome analysis
Transcriptome analysis was performed according to Sjöstedt et al. (2020). Transcriptome datasets were downloaded from The
Human Protein Atlas database (https://www.proteinatlas.org/; accessed June, 2021). Data for FAN1, MLH1 and MSH3 was parsed
for the cortex and striatum brain regions and graphs were generated using GraphPad Prism (v.9).
Mass-spectrometry
Lymphoblastoid cells, expressing endogenous levels of FAN1, and HEK293T cells transiently overexpressing myc-FAN1, were lysed
10min on ice using PBS, 1%NP-40, Benzonase and protease inhibitors and centrifuged 5min at 20,000 g to remove cell debris. Anti-
c-myc magnetic beads were incubated 2 h with HEK cell lysates. A sheep FAN1 antibody (Goold et al., 2019) was incubated for 1 h
with LB cell lysate and protein Gmagnetic beads were then added to the mix and incubated for an additional 1 h. Four washing steps
were performed using lysis buffer. Crosslinking was done using 1mMBS3 d0/d12 for 30min at 37C. The reaction was quenched for
20 min at 37C using ammonium bicarbonate at a final concentration of 100 mM. Prior to digestion, beads were resuspended in a
buffer containing 2MUrea, 100mM ammonium bicarbonate, 10mMDTT and denatured for 20min at room temperature under agita-
tion (1000 rpms) (Makowski et al., 2016). Samples were then alkylated, at room temperature and in the dark, using a final concen-
tration of 50 mM iodoacetamide for 20 min, and diluted with 50 mM ammonium bicarbonate solution to obtain a final concentration
of urea below 1 M. Digestion was performed using sequencing grade trypsin overnight at 37C. Samples were fractionated in 3 frac-
tions using C18-SCX StageTips prepared in-house as previously described (Rappsilber et al., 2007) with the following concentrations
of ammonium acetate: 200 mM, 1 M and 1.5 M. Prior to mass spectrometry analysis, samples were further processed using C18
StageTips.
Crosslinked peptide mixtures were resuspended in 3% acetonitrile, 0.1% formic acid and were analyzed by nano-LC-MS/MS us-
ing an Acquity M-Class system coupled to a Synapt G2Si mass spectrometer (Waters Corporation). Samples were loaded on the
system and desalted by a reversed-phase Symmetry C18 trap column (180 mm internal diameter, 20 mm length, 5 mm particle
size, Waters Corporation) at a flow rate of 8 mL/min for 3min in 99% solvent A (Solvent A: MS-grade water, 0.1% formic acid – solvent
B: Acetonitrile, 0.1% formic acid). Peptides were then separated using a linear gradient (0.3 mL/min, 35C; 3%–60% solvent B over
90 min) using a BEH130 C18 nanocolumn (75 mm internal diameter, 400 mm length, 1.7 mm particle size, Waters Corporation). The
mass spectrometer was operated in data-dependent acquisition mode using a mass range of 50-2000 Th for both MS and MS/MS
scans and scan times of 0.2 s and 0.3 s respectively. The tenmost intense precursor ions with a charge state between 3+ and 6+were
selected for fragmentation using the ‘mid’ collision energy ramp as described in James et al. (2019). Dynamic exclusion was used
with a 30 s window to prevent repeated selection of peptides.
Raw mass spectrometry files were converted to MGF (Mascot Generic Format) using PLGS (v3.0.2) using slow deisotoping algo-
rithm and automatic denoising for bothMSandMS/MSdata.MGF fileswere further converted tomzXMLwithMSConvert (Chambers
et al., 2012) using 32-bit binary encryption.
Crosslinking identification was performed using xQuest/xProphet (Leitner et al., 2014). Searches were performed using a database
containing the sequences of FAN1,MLH1, PMS2, FANCD2 and FANC1 using a search tolerance of 20 ppm. The amino acids involved
in crosslinking reactions parameter was set to K, S, T, Y and N-terminal amino acid. Up to three missed cleavages were allowed,
carbamidomethylation of cysteine was set as a fixed modification and oxidation of methionine was set as a variable modification.
Results were validated using xProphet with a 5% FDR.Cell Reports 36, 109649, August 31, 2021 e4
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using a modified version of Validate XL (James et al., 2019), and only considering crosslinks scoring higher than 20. For these cross-
links, the presence of light and heavy crosslinked doublets in the RAWMS files was confirmed. Automated generation of tables and
MGF files was done using an in-house Python script to allow crosslinking map representation using xiVIEW (Mendes et al., 2019).
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Perez-Riverol
et al., 2019) partner repository with the dataset identifier PXD023221 (Username: reviewer_pxd023221@ebi.ac.uk - Password:
lSFFWYxO). Code used for data processing is available at https://github.com/tmenneteau/xq-processing.
QUANTIFICATION AND STATISTICAL ANALYSIS
CAG expansion time courses were analyzed by linear regression in GraphPad Prism (v9) and slopes statistically compared by one-
way ANOVA. Multiple comparisons were corrected for with a False Discovery Rate (FDR) of 5%. Area under curve (AUC) data were
compared by a one-way ANOVA with an FDR correction of 5%. Significance was defined using FDR-corrected p values. Data be-
tween two groupswere analyzed by independent-samples t tests. *p < 0.05, ** p < 0.01, ***p < 0.001, ns = non-significant. The Brown-
Forsythe test was routinely used to check for homogeneity of variance. All statistical information can be found within figure legends.
For conservation analysis, the human FAN1 sequence was aligned in HomoloGene (NCBI) with common model species and visu-
alized with SnapGene software.e5 Cell Reports 36, 109649, August 31, 2021
